Sponsors

Commerce and COVID-19: a need for reconfiguration and transformation

The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2. Here, Mark Reed provides a commercial perspective and overview of the unprecedented times experienced over the past 12 months.

Looking back at 2020, I am quite sure that there isn’t a diagnostic manufacturing or distribution company in the UK, or even the world, that hasn’t been affected in some way by the SARS-CoV-2 pandemic, be that professionally or personally.

            As coronavirus continues to spread, and mutate, so testing methods have developed to detect the virus more effectively. Testing has always been integral to diagnosis, understanding its spread, and taking preventive measures to protect populations. The more rapid and reliable the test, the quicker there can be a diagnosis.

A brief timeline review

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026

Microbiology Society Annual Conference 2026

ICC Belfast, Northern Ireland
13 - 16 April, 2026